SHLT vs. PTWO, TOI, MRNS, CVM, ATHA, ONCY, CGTX, IFRX, SHOT, and ALRN
Should you be buying SHL Telemedicine stock or one of its competitors? The main competitors of SHL Telemedicine include Pono Capital Two (PTWO), Oncology Institute (TOI), Marinus Pharmaceuticals (MRNS), CEL-SCI (CVM), Athira Pharma (ATHA), Oncolytics Biotech (ONCY), Cognition Therapeutics (CGTX), InflaRx (IFRX), Safety Shot (SHOT), and Aileron Therapeutics (ALRN). These companies are all part of the "medical" sector.
SHL Telemedicine (NASDAQ:SHLT) and Pono Capital Two (NASDAQ:PTWO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, community ranking, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.
Pono Capital Two has lower revenue, but higher earnings than SHL Telemedicine.
In the previous week, Pono Capital Two had 2 more articles in the media than SHL Telemedicine. MarketBeat recorded 4 mentions for Pono Capital Two and 2 mentions for SHL Telemedicine. SHL Telemedicine's average media sentiment score of 1.45 beat Pono Capital Two's score of 1.20 indicating that SHL Telemedicine is being referred to more favorably in the media.
SHL Telemedicine presently has a consensus target price of $11.00, indicating a potential upside of 98.10%. Given SHL Telemedicine's higher possible upside, equities research analysts plainly believe SHL Telemedicine is more favorable than Pono Capital Two.
20.1% of SHL Telemedicine shares are held by institutional investors. Comparatively, 60.8% of Pono Capital Two shares are held by institutional investors. 63.9% of Pono Capital Two shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
SHL Telemedicine's return on equity of 0.00% beat Pono Capital Two's return on equity.
SHL Telemedicine received 1 more outperform votes than Pono Capital Two when rated by MarketBeat users.
Summary
SHL Telemedicine beats Pono Capital Two on 6 of the 11 factors compared between the two stocks.
Get SHL Telemedicine News Delivered to You Automatically
Sign up to receive the latest news and ratings for SHLT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SHLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SHL Telemedicine Competitors List
Related Companies and Tools
